MiniMed Connect kit, MiniMed Connect uploader, MiniMed Connect app, CareLink Connect (CareLink Personal)
Device Facts
| Record ID | K151236 |
|---|---|
| Device Name | MiniMed Connect kit, MiniMed Connect uploader, MiniMed Connect app, CareLink Connect (CareLink Personal) |
| Applicant | Medtronic Minimed, Inc. |
| Product Code | PJT · Clinical Chemistry |
| Decision Date | May 19, 2015 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1350 |
| Device Class | Class 2 |
Indications for Use
MiniMed Connect is intended to provide a secondary display of continuous glucose monitoring and/or insulin pump data on a suitable consumer electronic device to care partners and users of a MiniMed 530G system or Paradigm REAL-Time Revel system for the purposes of passive monitoring. MiniMed Connect system is not intended to replace the real-time display of continuous glucose monitor and/or insulin pump data on the primary display device (i.e., the sensor-augmented pump). All therapy decisions should be based on blood glucose measurements obtained from a blood glucose meter. The MiniMed Connect is not intended to analyze or modify the continuous glucose monitor data and/or insulin pump data that it receives. Nor is it intended to control any function of the connecting continuous glucose monitor system and/or insulin pump. The MiniMed Connect is not intended to serve as a replacement for a primary display device for the continuous glucose monitoring system and/or insulin pump data. The MiniMed Connect is not intended to receive information directly from the sensor or transmitter of a continuous glucose monitoring system.
Device Story
MiniMed Connect is a secondary display system for CGM and insulin pump data. It consists of a battery-powered uploader, a local mobile app, and a remote web-based monitoring module (CareLink Connect). The uploader receives data from the insulin pump via 916.5 MHz RF and converts it to 2.4 GHz Bluetooth Low Energy (BLE) for transmission to a consumer smartphone. The mobile app displays the data locally and uploads it to a cloud server for remote viewing by authorized care partners. The system is intended for passive monitoring only; it does not control the pump or CGM, nor does it replace the primary display. It is used in home or clinical environments by patients and care partners. Healthcare providers do not use the output for clinical decision-making; patients must rely on blood glucose meters for therapy and dosing decisions. The device benefits patients by providing remote visibility of glucose and pump status to caregivers.
Clinical Evidence
No clinical efficacy data. Bench testing verified accurate data transmission, secure storage, and encryption. Usability study with 25 patients using MiniMed Paradigm pumps assessed high/medium risk tasks; reported use errors were minor (pairing difficulties) and deemed nuisance issues. Readability analysis confirmed 8th-grade level for user guide.
Technological Characteristics
System includes a hardware uploader (916.5 MHz RF to 2.4 GHz BLE converter), mobile app (iOS), and web-based remote monitoring. Complies with IEC 60601-1, IEC 60601-1-2, IEC 60601-1-6, IEC 60601-1-11, IEC 62304, IEC 62366, ISO 14971, and ISO 15223-1. Data is encrypted on the mobile device and transmitted over secure channels.
Indications for Use
Indicated for users of MiniMed 530G or Paradigm REAL-Time Revel systems and their care partners for passive monitoring of continuous glucose monitoring (CGM) and insulin pump data on consumer electronic devices.
Regulatory Classification
Identification
A continuous glucose monitor (CGM) secondary alarm system is identified as a device intended to be used as a secondary alarm for a CGM to enable immediate awareness for potential clinical intervention to help assure patient safety.
Special Controls
A continuous glucose monitor secondary display must comply with the following special controls:
*Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9. The special controls for this device are:(1) Devices being marketed must include appropriate measures to protect against unauthorized access to data and unauthorized modification of data. (2) The labeling must prominently and conspicuously display a warning that states “Dosing decisions should not be made based on this device. The user should follow instructions on the continuous glucose monitoring system.” (3) The labeling for the device must include a statement that reads “This device is not intended to replace self-monitoring practices as advised by a physician.”
Predicate Devices
- Dexcom Share Direct Secondary Displays (DEN140038)